KALA BIO is no longer an ophthalmology developer in any operating sense. It is a Nasdaq Capital Market residual claim on a parked loan, a rented research-software license, and a listing that the exchange has already moved to eject. The investment debate is whether that residual still has option value as a public vehicle, or whether the post-trial recapitalization simply converted a failed clinical story into a thinner public shell.
The event that reset the equity was not a product launch. It was the September board decision to stop KPI-012 after the CHASE study missed complete healing of persistent corneal epithelial defects and showed no meaningful gap versus placebo. That stop triggered a workforce cut of about half the staff, a default notice from Oxford Finance the next day, and a sweep of substantially all cash from the bank accounts. The mechanism is simple: a single binary trial was also the covenant and cash story, so the miss did not merely retire a pipeline asset. It handed the secured lender the keys and forced a fire-sale recapitalization under David Lazar, then a second handover to Avi Minkowitz and a board slate tied to AK Holdings.
The tension is that the income statement now looks calmer only because almost nothing is being built. First-half net loss compressed to $3 million from $20 million a year earlier, but research spending fell to a rounding error and grant income from the California regenerative-medicine award disappeared with the trial. Cash on the June balance sheet is $229 thousand. The $7 million that used to sit in the bank now sits as a secured note to Minglemint Solutions, a private borrower, at eight percent. That note is the entire near-term liquidity story, and it is not cash.
What resolves the debate is observable and close. Nasdaq staff told the company on August 27 that the bid had sat under $1 for thirty sessions and that no automatic cure period applies because a one-for-fifty reverse split already landed in May. A Hearings Panel request stays suspension only while the panel sits. Beside that clock sit a September exclusive reseller pact with Virotek for ophthalmology genetic testing and a March license for Younet's Researgency research platform. Neither line has printed product revenue.